Antisense & RNAi Therapeutics Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)
Publication ⇒Jna-24 Delivery Time ⇒ 5-7 Business Days Report Code ⇒PBCHC289-10M-OT
License Type (Price in USD)
Antisense & RNAi Therapeutics Market – Report Overview
Pacific Business Consulting’s “Antisense & RNAi Therapeutics Market in 10MM – Market Outlook, Unmet Needs, Market Assessment & Forecast (2023-2030)” report offers a comprehensive understanding of Antisense & RNAi Therapeutics market, encompassing historical and projected market size data, along with market trends, market drivers, market barriers and unmet medical needs in the Ten Major Markets (10MM) of the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, China, Australia, and India.
The Antisense & RNAi Therapeutics market, valued at over US$ 4.8 Billion in 2022, is expected to experience a Compound Annual Growth Rate (CAGR) exceeding 10% from 2023 to 2030, potentially reaching beyond US$ 10.0 Billion by 2030.
Antisense and RNAi therapies have demonstrated enhanced therapeutic outcomes for rare diseases. Notably, Antisense Oligonucleotides (ASOs) have received approval for treating rare neurological conditions like Duchenne muscular dystrophy (DMD) and spinal muscular atrophy (SMA). This trend is anticipated to foster growth in the foreseeable future.
Globally, there are limited treatment options available for rare diseases. Consequently, there has been a gradual increase in funding and research initiatives dedicated to developing novel treatments for these conditions. Companies are actively engaging in various research activities to discover effective treatments. For instance, in August 2023, Agios Pharmaceuticals, Inc. collaborated with Alnylam Pharmaceuticals, Inc. to commercialize and develop a novel preclinical siRNA targeting TMPRSS6 for polycythemia vera (PV), a rare hematologic disorder. Such collaborative efforts by major players to develop therapeutics based on siRNA are expected to drive industry growth in the coming years.
Furthermore, research articles and studies focusing on antisense oligonucleotide and RNAi therapeutics as potential treatments for COVID-19 infections have been published. This emphasis on therapeutic approaches is projected to propel market growth. The antisense and RNAi market is marked by significant merger and acquisition (M&A) activities among leading players, driven by the desire to access these technologies and consolidate in a rapidly expanding market. Notably, major industry participants are acquiring firms specializing in RNAi therapeutics, such as Novartis acquiring DTx Pharma in July 2023.
Additionally, industry players are actively expanding their presence in various regions to enhance access to antisense and RNAi therapeutics globally. For instance, in March 2023, Alnylam Pharmaceuticals, Inc. expanded its collaboration with Medison Pharma to provide RNA interference (RNAi) therapeutics in multiple countries in central and eastern Europe. Such regional expansions by major players are expected to improve access to these therapeutic solutions.
Antisense technology, recognized for its efficacy in gene expression manipulation, has proven successful in treating various medical conditions. Companies are capitalizing on the advancements in antisense and RNAi technologies. For example, Agilent Technologies Inc. invested US$ 725 million in January 2023 to boost the manufacturing capability of therapeutic nucleic acids, meeting the growing demand for siRNA and antisense molecules.
The market is currently experiencing a high growth stage with an accelerating pace, characterized by significant innovation due to rapid technological advancements in RNAi therapeutics and RNA bioengineering. New entrants are bringing innovative technologies and platforms targeted at antisense and RNAi therapeutics, driving overall innovation in the industry. For instance, Switch Therapeutics, an emerging biotechnology company, announced its launch in March 2023, securing US$ 52 million in financing. With its Conditionally Activated siRNA (CASi), the company has developed a cell-selective gene knockdown platform poised to advance the next generation of RNAi therapies, contributing to the high innovation anticipated in the market.
Key players in the Antisense & RNAi Therapeutics segment, including Onis Pharmaceuticals, Inc., Benitec Biopharma Inc., Silence Therapeutics, Arbutus Biopharma, Bio-Path Holdings Inc., Antisense Therapeutics Limited., Switch Therapeutics, Olix Pharmaceuticals, Inc., GSK plc., Sanofi, Alnylam Pharmaceuticals, Inc., SciNeuro Pharmaceuticals, and Medison Pharma, are expected to play a crucial role in shaping the future landscape of Antisense & RNAi Therapeutics technologies through ongoing innovation.
Scope of Report
The report addresses critical subjects such as strategic competitor evaluation, market characterization, unmet needs, and the consequences of these elements for the Antisense & RNAi Therapeutics market. It also delves into the analysis of present and prospective market competition within the global Antisense & RNAi Therapeutics market.
Furthermore, the report offers an insightful examination of the primary industry drivers, constraints, and challenges. Each trend undergoes independent research to furnish qualitative analysis regarding its implications.
Reasons to Buy
- Develop your business strategies by gaining insights into the trends that shape and drive the Antisense & RNAi Therapeutics market across the 10MM (Ten Major Markets).
- Increase revenue by comprehending key trends, innovative products and technologies, market segments, and companies poised to influence the future of the 10MM Antisense & RNAi Therapeutics market.
- Craft effective sales and marketing strategies by thoroughly understanding the competitive landscape and analyzing the performance of various competitors.
- Identify emerging players with potentially robust product portfolios and devise strategic counter-strategies to gain a competitive advantage.
- Optimize your sales and marketing efforts by pinpointing market categories and segments that offer the greatest opportunities for consolidations, investments, and strategic partnerships.
- Executive Summary: Antisense & RNAi Therapeutics
- Global Market Outlook: Antisense & RNAi Therapeutics
- Competitive Intelligence Analysis: Antisense & RNAi Therapeutics
- Therapeutic Sector SWOT
- Technology Roadmap Analysis: Antisense & RNAi Therapeutics
- Market Background
- Drivers
- Restraints
- Opportunity
- Key Market Trends
- Key Unmet Needs
- Key Marketed Products Profile – Major Approved Products: Antisense & RNAi Therapeutics
- Product Profile
- Safety and Efficacy
- Regulatory Landscape
- Antisense & RNAi Therapeutics: Ten Major Market (10MM) – Market Analysis, By Technology
- Antisense RNA
- RNA Interference
- Antisense & RNAi Therapeutics: Ten Major Market (10MM) – Market Analysis, By Application
- Cancer
- Neurodegenerative Disorders
- Infectious Disease
- Cardiometabolic & Renal Disorders
- Genetic Disorders
- Others
- Antisense & RNAi Therapeutics: Ten Major Market (10MM) – Market Analysis, By Route of Administration
- Intravenous
- Subcutaneous
- Others
- Antisense & RNAi Therapeutics: Ten Major Market (10MM) – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- S. Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- K. Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- Germany Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- France Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- Italy Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- Spain Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- Japan Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- China Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- Australia Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- India Antisense & RNAi Therapeutics – Market Analysis
- Historical Market Analysis (US$ million), 2020-2022
- By Technology
- By Application
- By Route of Administration
- Current and Future Market Projections (US$ million), 2023-2030
- By Technology
- By Application
- By Route of Administration
- Historical Market Analysis (US$ million), 2020-2022
- Competitive Landscape
- Company Overview
- Product Portfolio
- Key Financials
- Sales Footprint
Note – All Major Company Profiles (Count up to 20) will be covered in the report
- Assumptions and Acronyms Used
- Research Methodology
- Secondary Research
- Primary Research
- Data Triangulation
- Geographic Scope
- The U.S., The U.K., Germany, France, Italy, Spain, Japan, China, Australia, and India
- Copyrights and Disclaimer
Customize Reports As Per Your Needs
Don’t see what you’re looking for? Get a report tailored to your specific requirements. Customize your report now!
Have A Question?
We are happy to assist you.
Phone:+919599779105
Email:info@pacificbusinessconsulting.com
RELATED PRODUCTS
Useful Links
Get In Touch
- Address : New Delhi, INDIA
- Phone No : +91-9599779105
- E-mail : info@pacificbusinessconsulting.com
